Share this article
Share this article
NEW YORK, March 16, 2021 /PRNewswire/ Over 17.9 million people die of cardiovascular diseases (CVDs) and 9.6 million of cancer each year, says the World Health Organization (WHO). With the mortality rate increasing every year, the global regenerative medicine market revenue is likely to grow to $39,012.0 million by 2030 from $8,186.9 million in 2019, at a 16.3% CAGR between 2020 and 2030.
This is because regenerative medicine is focused on repairing and recreating the tissues and cells destroyed by such diseases. In this regard, the regenerative medicine market is being driven by the rising geriatric population, as the elderly are more prone to chronic diseases than younger people. From 703 million in 2019, the number of people aged 65 and above around the world is set to reach 1.5 billion in 2050, as per the United Nations (UN).
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals.
“We are pleased to work with IDT to support Janssen’s efforts to make its COVID-19 vaccine available and accessible to as much of the world as possible,” said Rajeev Venkayya, President, Global Vaccine Business Unit at Takeda. “We also recognize the massive unmet need for a dengue vaccine and will work
Regenerative Medicine Market Revenue Worth $39,012 Million by 2030: P&S Intelligence prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) said that a subgroup analysis from phase 3 clinical trial supported efficacy of the investigational drug TAK-620 or maribavir over
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
March 15, 2021 08:00 ET | Source: Ovid Therapeutics Inc. Ovid Therapeutics Inc. New York, New York, UNITED STATES
Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing
Two pivotal Phase 3 trials of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome on track to commence in the second quarter of 2021, and upon the successful closing of the transaction, to be fully funded and conducted by Takeda